6533b82efe1ef96bd1292a07

RESEARCH PRODUCT

Single-centre, triple-blinded, randomised, 1-year, parallel-group, superiority study to compare the effects of Roux-en-Y gastric bypass and sleeve gastrectomy on remission of type 2 diabetes and β-cell function in subjects with morbid obesity: a protocol for the Obesity surgery in Tønsberg (Oseberg) study

Dag HofsøTor Olav Widerøe HillestadHeidi BorgeraasTor-ivar KarlsenTone Gretland ValderhaugMorten LindbergRune SandbuJolanta LorentzenJens Kristoffer HertelMarius SvanevikKåre I. BirkelandJøran HjelmesæthErling HalvorsenRonette L. KolotkinFarhat FatimaNils Petter KvanNjord NordstrandBirgitte SeipLine Kristin JohnsonHanne L. GulsethKathrine Aglen SeebergJohn Olav Grimnes

subject

Malemedicine.medical_specialtySleeve gastrectomyβ-cell functionmedicine.medical_treatment1843Gastric BypassBariatric Surgery030209 endocrinology & metabolismType 2 diabeteslaw.invention03 medical and health sciences0302 clinical medicineSuperiority TrialRandomized controlled trialClinical ProtocolslawGastrectomyDiabetes mellitusInternal medicineInsulin-Secreting CellsmedicineProtocolHumans030212 general & internal medicine1506VDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Kardiologi: 771Glycated Hemoglobinbusiness.industryNorwayGeneral Medicinemedicine.diseaseRoux-en-Y anastomosismorbid obesityObesity MorbidDiabetes and EndocrinologyTreatment OutcomeDiabetes Mellitus Type 2GastrectomyFemaleLaparoscopytype 2 diabetesbusinessEpidemiologic MethodsBody mass indexrandomised controlled trialsleeve gastrectomy

description

IntroductionBariatric surgery is increasingly recognised as an effective treatment option for subjects with type 2 diabetes and obesity; however, there is no conclusive evidence on the superiority of Roux-en-Y gastric bypass or sleeve gastrectomy. The Oseberg study was designed to compare the effects of gastric bypass and sleeve gastrectomy on remission of type 2 diabetes and β-cell function.Methods and analysisSingle-centre, randomised, triple-blinded, two-armed superiority trial carried out at the Morbid Obesity Centre at Vestfold Hospital Trust in Norway. Eligible patients with type 2 diabetes and obesity were randomly allocated in a 1:1 ratio to either gastric bypass or sleeve gastrectomy. The primary outcome measures are (1) the proportion of participants with complete remission of type 2 diabetes (HbA1c≤6.0% in the absence of blood glucose-lowering pharmacologic therapy) and (2) β-cell function expressed by the disposition index (calculated using the frequently sampled intravenous glucose tolerance test with minimal model analysis) 1 year after surgery.Ethics and disseminationThe protocol of the current study was reviewed and approved by the regional ethics committee on 12 September 2012 (ref: 2012/1427/REK sør-øst B). The results will be disseminated to academic and health professional audiences and the public via publications in international peer-reviewed journals and conferences. Participants will receive a summary of the main findings.Trial registration numberNCT01778738;Pre-results.

10.1136/bmjopen-2018-024573http://hdl.handle.net/11250/2636114